Challenges to environmental toxicology and epidemiology:: where do we stand and which way do we go?

被引:13
|
作者
Pesch, B
Brüning, T
Frentzel-Beyme, R
Johnen, G
Harth, V
Hoffmann, W
Ko, Y
Ranft, U
Traugott, UG
Thier, R
Taeger, D
Bolt, HM
机构
[1] Ruhr Univ Bochum, BGFA, D-44789 Bochum, Germany
[2] BIPS, D-28359 Bremen, Germany
[3] Ernst Moritz Arndt Univ Greifswald, D-17487 Greifswald, Germany
[4] Univ Bonn, Med Univ Poliklin Bonn, D-53111 Bonn, Germany
[5] Univ Dusseldorf, IUF, D-40225 Dusseldorf, Germany
[6] Europrote AG, D-16761 Hennigsdorf, Germany
[7] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia
[8] Univ Dortmund, Inst Arbeitsphysiol, IfADo, D-44139 Dortmund, Germany
关键词
exposure assessment; gene-environment interaction; toxicogenomics; pathomechanism;
D O I
10.1016/j.toxlet.2004.02.020
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Modern toxicology investigates a wide array of both old and new health hazards. Priority setting is needed to select agents for research from the plethora of exposure circumstances. The changing societies and a growing fraction of the aged have to be taken into consideration. A precise exposure assessment is of importance for risk estimation and regulation. Toxicology contributes to the exploration of pathomechanisms to specify the exposure metrics for risk estimation. Combined effects of co-existing agents are not yet sufficiently understood. Animal experiments allow a separate administration of agents which can not be disentangled by epidemiological means, but their value is limited for low exposure levels in many of today's settings. As an experimental science, toxicology has to keep pace with the rapidly growing knowledge about the language of the genome and the changing paradigms in cancer development. During the pioneer era of assembling a working draft of the human genome, toxicogenomics has been developed. Gene and pathway complexity have to be considered when investigating gene-environment interactions. For a best conduct of studies, modem toxicology needs a close liaison with many other disciplines like epidemiology and bioinformatics. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 50 条
  • [1] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    [J]. TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [2] Epidemiology of measles in Bavaria. Where do we stand, where do we want to go
    Schoenberger, K.
    Sing, A.
    Wildner, M.
    Liebl, B.
    Hautmann, W.
    [J]. GESUNDHEITSWESEN, 2015, 77
  • [3] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [4] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    [J]. SKELETAL MUSCLE, 2011, 1
  • [5] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    [J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [6] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    [J]. Skeletal Muscle, 1
  • [7] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    [J]. SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [8] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    [J]. MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [9] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    [J]. PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [10] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    [J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142